Article Text

Download PDFPDF
Original article
Vitreous levels of soluble vascular endothelial growth factor receptor (VEGFR)-1 in eyes with vitreoretinal diseases
  1. Ryo Asato1,
  2. Takeshi Kita1,
  3. Shuhei Kawahara1,
  4. Ryoichi Arita1,
  5. Yasutaka Mochizuki1,
  6. Lloyd Paul Aiello2,3,
  7. Tatsuro Ishibashi1
  1. 1Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  2. 2The Beetham Eye Institute at Joslin Diabetes Center, Boston, Massachusetts, USA
  3. 3Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
  1. Correspondence to Dr Takeshi Kita, Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan; kita{at}


Background/aims To determine the vitreous levels of soluble vascular endothelial growth factor receptor (sVEGFR)-1 in patients with various vitreoretinal diseases, and to investigate its correlation with patients' age and the activity of proliferative diabetic retinopathy (PDR).

Methods Vitreous fluid samples were obtained from 187 eyes of 170 patients who underwent vitrectomy for the treatment of idiopathic macular hole (MH, n=30), branch retinal vein occlusion (BRVO, n=37), central retinal vein occlusion (CRVO, n=27), diabetic macular oedema (DME, n=42) and PDR (n=51). The levels of sVEGFR-1 in the vitreous were measured by ELISA.

Results The levels of sVEGFR-1 (pg/ml) were not significantly different among each disease examined (MH 3900.1±1188.9, BRVO 3969.7±1741.6, CRVO 4897.7±1717.7, DME 3856.21±1374.7, PDR 4212.3±1474.9). There was a significant positive correlation between vitreous concentrations of sVEGFR-1 and patients' age (r=0.430, p<0.01). The sVEGFR-1 concentration in subjects with active PDR was significantly lower than in those with quiescent PDR (p<0.0001), even after being adjusted for age (p<0.0001).

Conclusions Vitreous concentrations of sVEGFR-1 increase with advancing age and are associated with quiescent rather than active PDR even after adjustment for age.

  • Vitreous fluid
  • soluble VEGFR-1
  • diabetic retinopathy
  • vitreous
  • retina
  • angiogenesis
  • pathology
  • treatment surgery
  • treatment medical
  • degeneration

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was supported in part by grants from the Ministry of Education, Science, Sports and Culture, Japan (Grant-in-Aid for Scientific Research #21592233).

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics approval was provided by the Institutional Review Board, Kyushu University Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh